摘要
目的:对比艾普拉唑与艾司奥美拉唑治疗消化性溃疡出血患者的临床效果及安全性。方法:本研究采用前瞻性随机对照研究方法。选取2023年2月—2024年9月就诊于山东大学第三人民医院的消化性溃疡出血患者100例,随机分为对照组(n=50)和观察组(n=50)。对照组采用艾司奥美拉唑治疗,观察组采用艾普拉唑治疗。对比两组的止血效果、凝血功能指标、炎症指标及安全性。结果:观察组止血成功率高于对照组(P<0.05)。治疗后,两组PT及APTT均短于治疗前,且观察组短于对照组(P<0.05)。治疗后,两组CRP、IL-1β和TNF-α均较治疗前降低,且观察组明显低于对照组(P<0.05)。治疗后,观察组不良反应发生率低于对照组(P<0.05)。结论:相较于艾司奥美拉唑,艾普拉唑治疗消化性溃疡出血患者的止血成功率更高,改善患者凝血功能及炎症因子水平,且具有一定安全性。
Objective:To compare the clinical efficacy and safety of Ilaprazole and Esomeprazole in the treatment of patients with peptic ulcer bleeding.Method:This study adopted a prospective randomized controlled research method.One hundred patients with peptic ulcer bleeding who were treated at the Jinan Third People's Hospital from February 2023 to September 2024 were selected and randomly divided into control group(n=50)and observation group(n=50).The control group was treated with Esomeprazole,while the observation group was treated with Ilaprazole.The hemostatic effects,coagulation function indicators,inflammatory indicators and safety of the two groups were compared.Result:The success rate of hemostasis in the observation group was higher than that in the control group(P<0.05).After treatment,the PT and APTT in both groups were shorter than those before treatment,and those in the observation group were shorter than those in the control group(P<0.05).After treatment,CRP,IL-1βand TNF-αin both groups were lower than those before treatment,and those in the observation group were significantly lower than those in the control group(P<0.05).After treatment,the incidence of adverse reactions in the observation group was lower than that in the control group(P<0.05).Conclusion:Compared with Esomeprazole,Ilaprazole has a higher hemostasis success rate in treating patients with peptic ulcer bleeding,improving the coagulation function and inflammatory factor levels of patients,and has certain safety.
作者
高家驹
杨娜
王冠华
周美艳
GAO Jiajü;YANG Na;WANG Guanhua;ZHOU Meiyan(Department of Gastroenterology,Jinan Third People's Hospital,Jinan 250132,China;不详)
出处
《中国医学创新》
2025年第36期120-123,共4页
Medical Innovation of China
